Neuromuscular Disorders
Volume 20, Issue 8 , Pages 479-492 , August 2010

Hereditary muscular dystrophies and the heart

  • M.C.E. Hermans

      Affiliations

    • Department of Neurology, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 43 3877059; fax: +31 43 3877055.
    • ,
  • Y.M. Pinto

      Affiliations

    • Department of Cardiology, Academic Medical Centre Amsterdam, The Netherlands
    • ,
  • I.S.J. Merkies

      Affiliations

    • Department of Neurology, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands
    • Department of Neurology, Spaarne Hospital, Hoofddorp, The Netherlands
    • ,
  • C.E.M. de Die-Smulders

      Affiliations

    • Department of Clinical Genetics, Maastricht University Medical Centre, Maastricht, The Netherlands
    • ,
  • H.J.G.M. Crijns

      Affiliations

    • Department of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands
    • ,
  • C.G. Faber

      Affiliations

    • Department of Neurology, Maastricht University Medical Centre, P.O. Box 5800, 6202 AZ, Maastricht, The Netherlands

Received 5 January 2010 ,Revised 19 April 2010 ,Accepted 21 April 2010.

References 

  1. OMIM® Online Mendelian Inheritance in Man. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD).
  2. Emery AE. Population frequencies of inherited neuromuscular diseases – a world survey. Neuromuscul Disord. 1991;1:19–29
  3. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord. 2002;12:926–929
  4. Bushby KM, Thambyayah M, Gardner-Medwin D. Prevalence and incidence of Becker muscular dystrophy. Lancet. 1991;337:1022–1024
  5. Emery AE, Skinner R. Clinical studies in benign (Becker type) X-linked muscular dystrophy. Clin Genet. 1976;10:189–201
  6. Bradley WG, Jones MZ, Mussini JM, Fawcett PR. Becker-type muscular dystrophy. Muscle Nerve. 1978;1:111–132
  7. Bushby KM, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. J Neurol. 1993;240:98–104
  8. Hoogerwaard EM, de Voogt WG, Wilde AA, van der Wouw PA, Bakker E, van Ommen GJ, et al. Evolution of cardiac abnormalities in Becker muscular dystrophy over a 13-year period. J Neurol. 1997;244:657–663
  9. Towbin JA, Hejtmancik JF, Brink P, Gelb B, Zhu XM, Chamberlain JS, et al. X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. Circulation. 1993;87:1854–1865
  10. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics. 1988;2:90–95
  11. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA. 1993;90:3710–3714
  12. Wallace GQ, McNally EM. Mechanisms of Muscle Degeneration, Regeneration, and Repair in the Muscular Dystrophies. Annu Rev Physiol. 2009;71:37–57
  13. Perloff JK. Cardiac rhythm and conduction in Duchenne’s muscular dystrophy: a prospective study of 20 patients. J Am Coll Cardiol. 1984;3:1263–1268
  14. Ishikawa K. Cardiac involvement in progressive muscular dystrophy of the Duchenne type. Jpn Heart J. 1997;38:163–180
  15. Sanyal SK, Johnson WW. Cardiac conduction abnormalities in children with Duchenne’s progressive muscular dystrophy: electrocardiographic features and morphologic correlates. Circulation. 1982;66:853–863
  16. Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol. 1990;26:271–277
  17. Yanagisawa A, Miyagawa M, Yotsukura M, Tsuya T, Shirato C, Ishihara T, et al. The prevalence and prognostic significance of arrhythmias in Duchenne type muscular dystrophy. Am Heart J. 1992;124:1244–1250
  18. Chenard AA, Becane HM, Tertrain F, de Kermadec JM, Weiss YA. Ventricular arrhythmia in Duchenne muscular dystrophy: prevalence, significance and prognosis. Neuromuscul Disord. 1993;3:201–206
  19. American Academy of Pediatrics . Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics. 2005;116:1569–1573
  20. Corrado G, Lissoni A, Beretta S, Terenghi L, Tadeo G, Foglia-Manzillo G, et al. Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy. Am J Cardiol. 2002;89:838–841
  21. Duboc D, Meune C, Lerebours G, Devaux JY, Vaksmann G, Becane HM. Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol. 2005;45:855–857
  22. Duboc D, Meune C, Pierre B, Wahbi K, Eymard B, Toutain A, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years’ follow-up. Am Heart J. 2007;154:596–602
  23. Cohn RD, van Erp C, Habashi JP, Soleimani AA, Klein EC, Lisi MT, et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med. 2007;13:204–210
  24. Chamberlain JS. ACE inhibitor bulks up muscle. Nat Med. 2007;13:125–126
  25. Steare SE, Dubowitz V, Benatar A. Subclinical cardiomyopathy in Becker muscular dystrophy. Br Heart J. 1992;68:304–308
  26. Nigro G, Comi LI, Politano L, Limongelli FM, Nigro V, De Rimini ML, et al. Evaluation of the cardiomyopathy in Becker muscular dystrophy. Muscle Nerve. 1995;18:283–291
  27. Saito M, Kawai H, Akaike M, Adachi K, Nishida Y, Saito S. Cardiac dysfunction with Becker muscular dystrophy. Am Heart J. 1996;132:642–647
  28. Melacini P, Fanin M, Danieli GA, Villanova C, Martinello F, Miorin M, et al. Myocardial involvement is very frequent among patients affected with subclinical Becker’s muscular dystrophy. Circulation. 1996;94:3168–3175
  29. Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th–9th June 2002, Naarden, the Netherlands. Neuromuscul Disord. 2003;13:166–172
  30. Connuck DM, Sleeper LA, Colan SD, Cox GF, Towbin JA, Lowe AM, et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2008;155:998–1005
  31. Jefferies JL, Eidem BW, Belmont JW, Craigen WJ, Ware SM, Fernbach SD, et al. Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation. 2005;112:2799–2804
  32. Kaspar RW, Allen HD, Ray WC, Alvarez CE, Kissel JT, Pestronk A, et al. Analysis of dystrophin deletion mutations predicts age of cardiomyopathy onset in Becker muscular dystrophy. Circ Cardiovasc Genet. 2009;2:544–551
  33. Politano L, Nigro V, Nigro G, Petretta VR, Passamano L, Papparella S, et al. Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies. JAMA. 1996;275:1335–1338
  34. Nolan MA, Jones OD, Pedersen RL, Johnston HM. Cardiac assessment in childhood carriers of Duchenne and Becker muscular dystrophies. Neuromuscul Disord. 2003;13:129–132
  35. Hoogerwaard EM, Bakker E, Ippel PF, Oosterwijk JC, Majoor-Krakauer DF, Leschot NJ, et al. Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in The Netherlands: a cohort study. Lancet. 1999;353:2116–2119
  36. Hoogerwaard EM, van der Wouw PA, Wilde AA, Bakker E, Ippel PF, Oosterwijk JC, et al. Cardiac involvement in carriers of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 1999;9:347–351
  37. Grain L, Cortina-Borja M, Forfar C, Hilton-Jones D, Hopkin J, Burch M. Cardiac abnormalities and skeletal muscle weakness in carriers of Duchenne and Becker muscular dystrophies and controls. Neuromuscul Disord. 2001;11:186–191
  38. Melacini P, Fanin M, Angelini A, Pegoraro E, Livi U, Danieli GA, et al. Cardiac transplantation in a Duchenne muscular dystrophy carrier. Neuromuscul Disord. 1998;8:585–590
  39. Davies JE, Winokur TS, Aaron MF, Benza RL, Foley BA, Holman WL. Cardiomyopathy in a carrier of Duchenne’s muscular dystrophy. J Heart Lung Transplant. 2001;20:781–784
  40. Holloway SM, Wilcox DE, Wilcox A, Dean JC, Berg JN, Goudie DR, et al. Life expectancy and death from cardiomyopathy amongst carriers of Duchenne and Becker muscular dystrophy in Scotland. Heart. 2008;94:633–636
  41. Berko BA, Swift M. X-linked dilated cardiomyopathy. N Engl J Med. 1987;316:1186–1191
  42. Ferlini A, Sewry C, Melis MA, Mateddu A, Muntoni F. X-linked dilated cardiomyopathy and the dystrophin gene. Neuromuscul Disord. 1999;9:339–346
  43. Bione S, Maestrini E, Rivella S, Mancini M, Regis S, Romeo G, et al. Identification of a novel X-linked gene responsible for Emery–Dreifuss muscular dystrophy. Nat Genet. 1994;8:323–327
  44. Manilal S, Nguyen TM, Sewry CA, Morris GE. The Emery–Dreifuss muscular dystrophy protein, emerin, is a nuclear membrane protein. Hum Mol Genet. 1996;5:801–808
  45. Nagano A, Koga R, Ogawa M, Kurano Y, Kawada J, Okada R, et al. Emerin deficiency at the nuclear membrane in patients with Emery–Dreifuss muscular dystrophy. Nat Genet. 1996;12:254–259
  46. Manilal S, Recan D, Sewry CA, Hoeltzenbein M, Llense S, Leturcq F, et al. Mutations in Emery–Dreifuss muscular dystrophy and their effects on emerin protein expression. Hum Mol Genet. 1998;7:855–864
  47. Bonne G, Di Barletta MR, Varnous S, Becane HM, Hammouda EH, Merlini L, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery–Dreifuss muscular dystrophy. Nat Genet. 1999;21:285–288
  48. Raffaele Di Barletta M, Ricci E, Galluzzi G, Tonali P, Mora M, Morandi L, et al. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery–Dreifuss muscular dystrophy. Am J Hum Genet. 2000;66:1407–1412
  49. Benedetti S, Merlini L. Laminopathies: from the heart of the cell to the clinics. Curr Opin Neurol. 2004;17:553–560
  50. Bonne G, Mercuri E, Muchir A, Urtizberea A, Becane HM, Recan D, et al. Clinical and molecular genetic spectrum of autosomal dominant Emery–Dreifuss muscular dystrophy due to mutations of the lamin A/C gene. Ann Neurol. 2000;48:170–180
  51. Manilal S, Sewry CA, Pereboev A, Man N, Gobbi P, Hawkes S, et al. Distribution of emerin and lamins in the heart and implications for Emery–Dreifuss muscular dystrophy. Hum Mol Genet. 1999;8:353–359
  52. Bonne G, Leturcq F, Récan-Budiartha D, Ben Yaou R. (Updated 21 November 2007). Emery–Dreifuss muscular dystrophy. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. Available at <http://www.genetests.org> [accessed 14 September 2009]; 1997–2009.
  53. Zhang Q, Bethmann C, Worth NF, Davies JD, Wasner C, Feuer A, et al. Nesprin-1 and -2 are involved in the pathogenesis of Emery Dreifuss muscular dystrophy and are critical for nuclear envelope integrity. Hum Mol Genet. 2007;16:2816–2833
  54. Tsuchiya Y, Hase A, Ogawa M, Yorifuji H, Arahata K. Distinct regions specify the nuclear membrane targeting of emerin, the responsible protein for Emery–Dreifuss muscular dystrophy. Eur J Biochem. 1999;259:859–865
  55. Lammerding J, Hsiao J, Schulze PC, Kozlov S, Stewart CL, Lee RT. Abnormal nuclear shape and impaired mechanotransduction in emerin-deficient cells. J Cell Biol. 2005;170:781–791
  56. Bakay M, Wang Z, Melcon G, Schiltz L, Xuan J, Zhao P, et al. Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain. 2006;129:996–1013
  57. Waters DD, Nutter DO, Hopkins LC, Dorney ER. Cardiac features of an unusual X-linked humeroperoneal neuromuscular disease. N Engl J Med. 1975;293:1017–1022
  58. Voit T, Krogmann O, Lenard HG, Neuen-Jacob E, Wechsler W, Goebel HH, et al. Emery–Dreifuss muscular dystrophy: disease spectrum and differential diagnosis. Neuropediatrics. 1988;19:62–71
  59. Bialer MG, McDaniel NL, Kelly TE. Progression of cardiac disease in Emery–Dreifuss muscular dystrophy. Clin Cardiol. 1991;14:411–416
  60. Fishbein MC, Siegel RJ, Thompson CE, Hopkins LC. Sudden death of a carrier of X-linked Emery–Dreifuss muscular dystrophy. Ann Intern Med. 1993;119:900–905
  61. Merlini L, Granata C, Dominici P, Bonfiglioli S. Emery–Dreifuss muscular dystrophy: report of five cases in a family and review of the literature. Muscle Nerve. 1986;9:481–485
  62. Funakoshi M, Tsuchiya Y, Arahata K. Emerin and cardiomyopathy in Emery–Dreifuss muscular dystrophy. Neuromuscul Disord. 1999;9:108–114
  63. Boriani G, Gallina M, Merlini L, Bonne G, Toniolo D, Amati S, et al. Clinical relevance of atrial fibrillation/flutter, stroke, pacemaker implant, and heart failure in Emery–Dreifuss muscular dystrophy: a long-term longitudinal study. Stroke. 2003;34:901–908
  64. Sakata K, Shimizu M, Ino H, Yamaguchi M, Terai H, Fujino N, et al. High incidence of sudden cardiac death with conduction disturbances and atrial cardiomyopathy caused by a nonsense mutation in the STA gene. Circulation. 2005;111:3352–3358
  65. van der Kooi AJ, Ledderhof TM, de Voogt WG, Res CJ, Bouwsma G, Troost D, et al. A newly recognized autosomal dominant limb girdle muscular dystrophy with cardiac involvement. Ann Neurol. 1996;39:636–642
  66. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med. 1999;341:1715–1724
  67. Becane HM, Bonne G, Varnous S, Muchir A, Ortega V, Hammouda EH, et al. High incidence of sudden death with conduction system and myocardial disease due to lamins A and C gene mutation. Pacing Clin Electrophysiol. 2000;23:1661–1666
  68. Brodsky GL, Muntoni F, Miocic S, Sinagra G, Sewry C, Mestroni L. Lamin A/C gene mutation associated with dilated cardiomyopathy with variable skeletal muscle involvement. Circulation. 2000;101:473–476
  69. van Berlo JH, de Voogt WG, van der Kooi AJ, van Tintelen JP, Bonne G, Yaou RB, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A/C mutations portend a high risk of sudden death?. J Mol Med. 2005;83:79–83
  70. Meune C, Van Berlo JH, Anselme F, Bonne G, Pinto YM, Duboc D. Primary prevention of sudden death in patients with lamin A/C gene mutations. N Engl J Med. 2006;354:209–210
  71. Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol. 2008;52:1250–1260
  72. Bushby K. The limb-girdle muscular dystrophies. In:  Emery AE editors. Diagnostic criteria for neuromuscular disorders. London: Royal Society of Medicine Press; 1997;p. 17–22
  73. van der Kooi AJ, Barth PG, Busch HF, de Haan R, Ginjaar HB, van Essen AJ, et al. The clinical spectrum of limb girdle muscular dystrophy. A survey in The Netherlands. Brain. 1996;119(Pt 5):1471–1480
  74. Laval SH, Bushby KM. Limb-girdle muscular dystrophies – from genetics to molecular pathology. Neuropathol Appl Neurobiol. 2004;30:91–105
  75. Minetti C, Sotgia F, Bruno C, Scartezzini P, Broda P, Bado M, et al. Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. Nat Genet. 1998;18:365–368
  76. Hauser MA, Conde CB, Kowaljow V, Zeppa G, Taratuto AL, Torian UM, et al. Myotilin Mutation found in second pedigree with LGMD1A. Am J Hum Genet. 2002;71:1428–1432
  77. Messina DN, Speer MC, Pericak-Vance MA, McNally EM. Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. Am J Hum Genet. 1997;61:909–917
  78. Crosbie RH, Lim LE, Moore SA, Hirano M, Hays AP, Maybaum SW, et al. Molecular and genetic characterization of sarcospan: insights into sarcoglycan–sarcospan interactions. Hum Mol Genet. 2000;9:2019–2027
  79. Holt KH, Campbell KP. Assembly of the sarcoglycan complex. Insights for muscular dystrophy. J Biol Chem. 1998;273:34667–34670
  80. Fanin M, Duggan DJ, Mostacciuolo ML, Martinello F, Freda MP, Soraru G, et al. Genetic epidemiology of muscular dystrophies resulting from sarcoglycan gene mutations. J Med Genet. 1997;34:973–977
  81. Duggan DJ, Manchester D, Stears KP, Mathews DJ, Hart C, Hoffman EP. Mutations in the delta-sarcoglycan gene are a rare cause of autosomal recessive limb-girdle muscular dystrophy (LGMD2). Neurogenetics. 1997;1:49–58
  82. Vainzof M, Passos-Bueno MR, Pavanello RC, Marie SK, Oliveira AS, Zatz M. Sarcoglycanopathies are responsible for 68% of severe autosomal recessive limb-girdle muscular dystrophy in the Brazilian population. J Neurol Sci. 1999;164:44–49
  83. Eymard B, Romero NB, Leturcq F, Piccolo F, Carrie A, Jeanpierre M, et al. Primary adhalinopathy (alpha-sarcoglycanopathy): clinical, pathologic, and genetic correlation in 20 patients with autosomal recessive muscular dystrophy. Neurology. 1997;48:1227–1234
  84. Barresi R, Confalonieri V, Lanfossi M, Di Blasi C, Torchiana E, Mantegazza R, et al. Concomitant deficiency of beta- and gamma-sarcoglycans in 20 alpha-sarcoglycan (adhalin)-deficient patients: immunohistochemical analysis and clinical aspects. Acta Neuropathol. 1997;94:28–35
  85. Angelini C, Fanin M, Freda MP, Duggan DJ, Siciliano G, Hoffman EP. The clinical spectrum of sarcoglycanopathies. Neurology. 1999;52:176–179
  86. Melacini P, Fanin M, Duggan DJ, Freda MP, Berardinelli A, Danieli GA, et al. Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Muscle Nerve. 1999;22:473–479
  87. Politano L, Nigro V, Passamano L, Petretta V, Comi LI, Papparella S, et al. Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. Neuromuscul Disord. 2001;11:178–185
  88. Barresi R, Di Blasi C, Negri T, Brugnoni R, Vitali A, Felisari G, et al. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by beta sarcoglycan mutations. J Med Genet. 2000;37:102–107
  89. Fanin M, Melacini P, Boito C, Pegoraro E, Angelini C. LGMD2E patients risk developing dilated cardiomyopathy. Neuromuscul Disord. 2003;13:303–309
  90. Brockington M, Yuva Y, Prandini P, Brown SC, Torelli S, Benson MA, et al. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet. 2001;10:2851–2859
  91. Beltran-Valero de Bernabe D, Voit T, Longman C, Steinbrecher A, Straub V, Yuva Y, et al. J Med Genet. 2004;41:e61
  92. Muntoni F, Torelli S, Brockington M. Muscular dystrophies due to glycosylation defects. Neurotherapeutics. 2008;5:627–632
  93. Mercuri E, Brockington M, Straub V, Quijano-Roy S, Yuva Y, Herrmann R, et al. Phenotypic spectrum associated with mutations in the fukutin-related protein gene. Ann Neurol. 2003;53:537–542
  94. Poppe M, Bourke J, Eagle M, Frosk P, Wrogemann K, Greenberg C, et al. Cardiac and respiratory failure in limb-girdle muscular dystrophy 2I. Ann Neurol. 2004;56:738–741
  95. Boito CA, Melacini P, Vianello A, Prandini P, Gavassini BF, Bagattin A, et al. Clinical and molecular characterization of patients with limb-girdle muscular dystrophy type 2I. Arch Neurol. 2005;62:1894–1899
  96. Sveen ML, Thune JJ, Kober L, Vissing J. Cardiac involvement in patients with limb-girdle muscular dystrophy type 2 and Becker muscular dystrophy. Arch Neurol. 2008;65:1196–1201
  97. Wahbi K, Meune C, Hamouda el H, Stojkovic T, Laforet P, Becane HM, et al. Cardiac assessment of limb-girdle muscular dystrophy 2I patients: an echography, Holter ECG and magnetic resonance imaging study. Neuromuscul Disord. 2008;18:650–655
  98. Beckmann JS, Brown RH, Muntoni F, Urtizberea A, Bonnemann C, Bushby KM. 66th/67th ENMC sponsored international workshop: The limb-girdle muscular dystrophies, 26–28 March 1999, Naarden, The Netherlands. Neuromuscul Disord. 1999;9:436–445
  99. Fayssoil A. Cardiac diseases in sarcoglycanopathies. Int J Cardiol 2009.
  100. Harper PS. Myotonic dystrophy. London: Saunders; 2001;
  101. Höweler CJ, Busch HF, Geraedts JP, Niermeijer MF, Staal A. Anticipation in myotonic dystrophy: fact or fiction?. Brain. 1989;112:779–797
  102. Harley HG, Rundle SA, MacMillan JC, Myring J, Brook JD, Crow S, et al. Size of the unstable CTG repeat sequence in relation to phenotype and parental transmission in myotonic dystrophy. Am J Hum Genet. 1993;52:1164–1174
  103. Mathieu J, Allard P, Potvin L, Prevost C, Begin P. A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology. 1999;52:1658–1662
  104. de Die-Smulders CE, Höweler CJ, Thijs C, Mirandolle JF, Anten HB, Smeets HJ, et al. Age and causes of death in adult-onset myotonic dystrophy. Brain. 1998;121:1557–1563
  105. Groh WJ, Groh MR, Saha C, Kincaid JC, Simmons Z, Ciafaloni E, et al. Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1. N Engl J Med. 2008;358:2688–2697
  106. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, Aburatani H, et al. Cell. 1992;69:385
  107. Berul CI, Maguire CT, Gehrmann J, Reddy S. Progressive atrioventricular conduction block in a mouse myotonic dystrophy model. J Interv Card Electrophysiol. 2000;4:351–358
  108. Klesert TR, Otten AD, Bird TD, Tapscott SJ. Trinucleotide repeat expansion at the myotonic dystrophy locus reduces expression of DMAHP. Nat Genet. 1997;16:402–406
  109. Ranum LP, Day JW. Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet. 2004;74:793–804
  110. Bigot A, Klein AF, Gasnier E, Jacquemin V, Ravassard P, Butler-Browne G, et al. Large CTG repeats trigger p16-dependent premature senescence in myotonic dystrophy type 1 muscle precursor cells. Am J Pathol. 2009;174:1435–1442
  111. Bassez G, Lazarus A, Desguerre I, Varin J, Laforet P, Becane HM, et al. Severe cardiac arrhythmias in young patients with myotonic dystrophy type 1. Neurology. 2004;63:1939–1941
  112. Phillips MF, Harper PS. Cardiac disease in myotonic dystrophy. Cardiovasc Res. 1997;33:13–22
  113. Hawley RJ, Milner MR, Gottdiener JS, Cohen A. Myotonic heart disease: a clinical follow-up. Neurology. 1991;41:259–262
  114. Fragola PV, Luzi M, Calo L, Antonini G, Borzi M, Frongillo D, et al. Cardiac involvement in myotonic dystrophy. Am J Cardiol. 1994;74:1070–1072
  115. Lazarus A, Varin J, Babuty D, Anselme F, Coste J, Duboc D. Long-term follow-up of arrhythmias in patients with myotonic dystrophy treated by pacing: a multicenter diagnostic pacemaker study. J Am Coll Cardiol. 2002;40:1645–1652
  116. Lazarus A, Varin J, Ounnoughene Z, Radvanyi H, Junien C, Coste J, et al. Relationships among electrophysiological findings and clinical status, heart function, and extent of DNA mutation in myotonic dystrophy. Circulation. 1999;99:1041–1046
  117. Nguyen HH, Wolfe JT, Holmes DR, Edwards WD. Pathology of the cardiac conduction system in myotonic dystrophy: a study of 12 cases. J Am Coll Cardiol. 1988;11:662–671
  118. De Ambroggi L, Raisaro A, Marchiano V, Radice S, Meola G. Cardiac involvement in patients with myotonic dystrophy: characteristic features of magnetic resonance imaging. Eur Heart J. 1995;16:1007–1010
  119. Bhakta D, Lowe MR, Groh WJ. Prevalence of structural cardiac abnormalities in patients with myotonic dystrophy type I. Am Heart J. 2004;147:224–227
  120. Orndahl G, Thulesius O, Enestroem S, Dehlin O. The heart in myotonic disease. Acta Med Scand. 1964;176:479–491
  121. Hermans MC, Faber CG, Pinto YM. Sudden death in myotonic dystrophy. N Engl J Med. 2008;359:1626–1628[author reply 1328–29]
  122. Bachinski LL, Udd B, Meola G, Sansone V, Bassez G, Eymard B, et al. Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet. 2003;73:835–848
  123. Day JW, Ricker K, Jacobsen JF, Rasmussen LJ, Dick KA, Kress W, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology. 2003;60:657–664
  124. Meola G, Moxley RT. Myotonic dystrophy type 2 and related myotonic disorders. J Neurol. 2004;251:1173–1182
  125. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W, Naylor SL, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science. 2001;293:864–867
  126. Botta A, Vallo L, Rinaldi F, Bonifazi E, Amati F, Biancolella M, et al. Gene expression analysis in myotonic dystrophy: indications for a common molecular pathogenic pathway in DM1 and DM2. Gene Expr. 2007;13:339–351
  127. Wahbi K, Meune C, Becane HM, Laforet P, Bassez G, Lazarus A, et al. Left ventricular dysfunction and cardiac arrhythmias are frequent in type 2 myotonic dystrophy: A case control study. Neuromuscul Disord. 2009;19:468–472
  128. von zur Muhlen F, Klass C, Kreuzer H, Mall G, Giese A, Reimers CD. Cardiac involvement in proximal myotonic myopathy. Heart. 1998;79:619–621
  129. Schoser BG, Ricker K, Schneider-Gold C, Hengstenberg C, Durre J, Bultmann B, et al. Sudden cardiac death in myotonic dystrophy type 2. Neurology. 2004;63:2402–2404
  130. Schenk S, Loscher S, Mickley F, Hartmann A. Female patient with proximal myotonic myopathy and ventricular tachycardia. Z Kardiol. 2005;94:754–760
  131. Udd B, Meola G, Krahe R, Thornton C, Ranum LP, Bassez G, et al. 140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management. Neuromuscul Disord. 2006;16:403–413
  132. Finsterer J. Myotonic dystrophy type 2. Eur J Neurol. 2002;9:441–447
  133. Mostacciuolo ML, Miorin M, Martinello F, Angelini C, Perini P, Trevisan CP. Genetic epidemiology of congenital muscular dystrophy in a sample from north-east Italy. Hum Genet. 1996;97:277–279
  134. Allamand V, Guicheney P. Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM#156225, LAMA2 gene coding for alpha2 chain of laminin). Eur J Hum Genet. 2002;10:91–94
  135. Toda T, Kobayashi K, Kondo-Iida E, Sasaki J, Nakamura Y. The Fukuyama congenital muscular dystrophy story. Neuromuscul Disord. 2000;10:153–159
  136. Nakanishi T, Sakauchi M, Kaneda Y, Tomimatsu H, Saito K, Nakazawa M, et al. Cardiac involvement in Fukuyama-type congenital muscular dystrophy. Pediatrics. 2006;117:e1187–1192
  137. Brockington M, Blake DJ, Prandini P, Brown SC, Torelli S, Benson MA, et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J Hum Genet. 2001;69:1198–1209
  138. Dubowitz V. 41st ENMC International Workshop on Congenital Muscular Dystrophy 8–10 March 1996, Naarden, The Netherlands. Neuromuscul Disord. 1996;6:295–306
  139. Spyrou N, Philpot J, Foale R, Camici PG, Muntoni F. Evidence of left ventricular dysfunction in children with merosin-deficient congenital muscular dystrophy. Am Heart J. 1998;136:474–476
  140. Fardeau M, Tome FM, Helbling-Leclerc A, Evangelista T, Ottolini A, Chevallay M, et al. Congenital muscular dystrophy with merosin deficiency: clinical, histopathological, immunocytochemical and genetic analysis. Rev Neurol (Paris). 1996;152:11–19
  141. Mukoyama M, Hizawa K, Kagawa N, Takahashi K. The life spans, cause of death and pathological findings of Fukuyama type congenital muscular dystrophy-analysis of 24 autopsy cases. Rinsho Shinkeigaku. 1993;33:1154–1156
  142. Lunt PW. 44th ENMC International Workshop: Facioscapulohumeral Muscular Dystrophy: Molecular Studies 19–21 July 1996, Naarden, The Netherlands. Neuromuscul Disord. 1998;8:126–130
  143. van Deutekom JC, Wijmenga C, van Tienhoven EA, Gruter AM, Hewitt JE, Padberg GW, et al. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2kb tandemly repeated unit. Hum Mol Genet. 1993;2:2037–2042
  144. Stevenson WG, Perloff JK, Weiss JN, Anderson TL. Facioscapulohumeral muscular dystrophy: evidence for selective, genetic electrophysiologic cardiac involvement. J Am Coll Cardiol. 1990;15:292–299
  145. de Visser M, de Voogt WG, la Riviere GV. The heart in Becker muscular dystrophy, facioscapulohumeral dystrophy, and Bethlem myopathy. Muscle Nerve. 1992;15:591–596
  146. Laforet P, de Toma C, Eymard B, Becane HM, Jeanpierre M, Fardeau M, et al. Cardiac involvement in genetically confirmed facioscapulohumeral muscular dystrophy. Neurology. 1998;51:1454–1456
  147. Trevisan CP, Pastorello E, Armani M, Angelini C, Nante G, Tomelleri G, et al. Facioscapulohumeral muscular dystrophy and occurrence of heart arrhythmia. European neurology. 2006;56:1–5
  148. Selcen D. Myofibrillar myopathies. Curr Opin Neurol. 2008;21:585–589
  149. Goldfarb LG, Dalakas MC. Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease. J Clin Invest. 2009;119:1806–1813
  150. Vicart P, Caron A, Guicheney P, Li Z, Prevost MC, Faure A, et al. A missense mutation in the alphaB-crystallin chaperone gene causes a desmin-related myopathy. Nat Genet. 1998;20:92–95
  151. Selcen D, Engel AG. Myofibrillar myopathy caused by novel dominant negative alpha B-crystallin mutations. Ann Neurol. 2003;54:804–810
  152. Selcen D, Muntoni F, Burton BK, Pegoraro E, Sewry C, Bite AV, et al. Mutation in BAG3 causes severe dominant childhood muscular dystrophy. Ann Neurol. 2009;65:83–89
  153. Melberg A, Oldfors A, Blomstrom-Lundqvist C, Stalberg E, Carlsson B, Larrson E, et al. Autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy linked to chromosome 10q. Ann Neurol. 1999;46:684–692
  154. Griggs R, Vihola A, Hackman P, Talvinen K, Haravuori H, Faulkner G, et al. Zaspopathy in a large classic late-onset distal myopathy family. Brain. 2007;130:1477–1484
  155. Nishino I, Fu J, Tanji K, Yamada T, Shimojo S, Koori T, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature. 2000;406:906–910
  156. Murakami N, Goto Y, Itoh M, Katsumi Y, Wada T, Ozawa E, et al. Sarcolemmal indentation in cardiomyopathy with mental retardation and vacuolar myopathy. Neuromuscul Disord. 1995;5:149–155
  157. Sugie K, Yamamoto A, Murayama K, Oh SJ, Takahashi M, Mora M, et al. Clinicopathological features of genetically confirmed Danon disease. Neurology. 2002;58:1773–1778
  158. Spencer CT, Bryant RM, Day J, Gonzalez IL, Colan SD, Thompson WR, et al. Cardiac and clinical phenotype in Barth syndrome. Pediatrics. 2006;118:e337–346
  159. Danek A, Rubio JP, Rampoldi L, Ho M, Dobson-Stone C, Tison F, et al. McLeod neuroacanthocytosis: genotype and phenotype. Ann Neurol. 2001;50:755–764
  160. Windpassinger C, Schoser B, Straub V, Hochmeister S, Noor A, Lohberger B, et al. An X-linked myopathy with postural muscle atrophy and generalized hypertrophy, termed XMPMA, is caused by mutations in FHL1. Am J Hum Genet. 2008;82:88–99
  161. Schessl J, Taratuto AL, Sewry C, Battini R, Chin SS, Maiti B, et al. Clinical, histological and genetic characterization of reducing body myopathy caused by mutations in FHL1. Brain. 2009;132:452–464
  162. Carmignac V, Salih MA, Quijano-Roy S, Marchand S, Al Rayess MM, Mukhtar MM, et al. C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy. Ann Neurol. 2007;61:340–351
  163. Overeem S, Schelhaas HJ, Blijham PJ, Grootscholten MI, ter Laak HJ, Timmermans J, et al. Symptomatic distal myopathy with cardiomyopathy due to a MYH7 mutation. Neuromuscul Disord. 2007;17:490–493
  164. Uro-Coste E, Arne-Bes MC, Pellissier JF, Richard P, Levade T, Heitz F, et al. Striking phenotypic variability in two familial cases of myosin storage myopathy with a MYH7 Leu1793pro mutation. Neuromuscul Disord. 2009;19:163–166
  165. Manzur AY, Kinali M, Muntoni F. Update on the management of Duchenne muscular dystrophy. Arch Dis Child. 2008;93:986–990
  166. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008 [CD003725].
  167. Silversides CK, Webb GD, Harris VA, Biggar DW. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol. 2003;91:769–772
  168. Bauer R, Straub V, Blain A, Bushby K, MacGowan GA. Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail. 2009;11:463–471
  169. Cossu G, Sampaolesi M. New therapies for Duchenne muscular dystrophy: challenges, prospects and clinical trials. Trends Mol Med. 2007;13:520–526
  170. Wheeler TM. Myotonic dystrophy: therapeutic strategies for the future. Neurotherapeutics. 2008;5:592–600

PII: S0960-8966(10)00189-6

doi: 10.1016/j.nmd.2010.04.008

Neuromuscular Disorders
Volume 20, Issue 8 , Pages 479-492 , August 2010

Article Tools

* Image Usage & Resolution